Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Oslo University Hospital HF
Sponsor

Oslo University Hospital HF

Norway Taarnbygget, Kirkeveien 166, 0450 Oslo, Norway

About the sponsor

Research activity includes follicular lymphoma, multiple myeloma, acute lymphoblastic leukemia, lymphoblastic lymphoma, and graft-versus-host disease, with a strong interest in targeted immune-based treatment strategies and disease monitoring in blood cancers.

  • Follicular lymphoma
  • Multiple myeloma
  • Acute lymphoblastic leukemia
  • Graft-versus-host disease

Additional work spans minimal residual disease-guided treatment, CAR T-cell therapy, and vaccine-based immunotherapy in relapsed or high-risk haematological malignancies.

About Specializations

Oslo University Hospital HF runs clinical trials in conditions such as Renal transplant, Plasma cell myeloma, Arteriovenous malformation, Juvenile idiopathic arthritis, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

78 clinical trials

Acute lymphocytic leukaemia+1

Recruiting

Study of TdT-3 cell therapy safety in patients aged 1 year and older with relapsed or refractory acute leukemia or lymphoblastic lymphoma

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:TDT-3
  • Sponsor:Oslo University Hospital HF

Pseudomyxoma peritonei

Recruiting

A study of Pseudovax, molgramostim and tislelizumab combination therapy for patients with pseudomyxoma peritonei cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Molgramostim
  • Sponsor:Oslo University Hospital HF

Interstitial lung disease

Recruiting

Study of Rituximab versus Placebo to Improve Lung Function in Patients with Granulomatous Lymphocytic Interstitial Lung Disease (GLILD)

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Oslo University Hospital HF

Periarthritis

Recruiting

Study on Frozen Shoulder: Evaluating the Effectiveness of Physiotherapy, Triamcinolone Acetonide, and Lidocaine in Improving Shoulder Function and Reducing Pain

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Cetrimide
  • Sponsor:Oslo University Hospital HF

Migraine

Recruiting

Study on Reducing Chronic Migraine Days with CGRP Antibodies and Botulinum Toxin A in Adults Aged 18-70

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Erenumab
  • Sponsor:Oslo University Hospital HF

Amyotrophic lateral sclerosis

Recruiting

Study on the Effects of ILB and Riluzole for Patients with Amyotrophic Lateral Sclerosis (ALS)

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Riluzole
  • Sponsor:Oslo University Hospital HF

Hydrocephalus

Recruiting

Study on Water Absorption in the Brain for Adults with Hydrocephalus Using O15-Water

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:O15-WATER
  • Sponsor:Oslo University Hospital HF

Sepsis

Recruiting

Study on Meropenem Dosing for Patients with Serious Infections in Intensive Care

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Linezolid
  • Sponsor:Oslo University Hospital HF

Ischaemic stroke

Recruiting

Study on the Effectiveness of Tenecteplase in Patients with Acute Ischemic Stroke Taking Rivaroxaban, Apixaban, or Edoxaban

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:Oslo University Hospital HF

Liver operation

Recruiting

Study on Dalteparin Sodium and Enoxaparin Sodium for Preventing Blood Clots in Patients Undergoing Liver Surgery

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Dalteparin Sodium
  • Sponsor:Oslo University Hospital HF

Central nervous system neoplasm+2

Recruiting

Study of Gadobutrol for MRI in Adults with Cerebrospinal Fluid Disorders, Including Hydrocephalus and Brain Tumors

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Gadobutrol
  • Sponsor:Oslo University Hospital HF

Neoplasm malignant

Recruiting

Study on Dabrafenib, Trametinib, and Imatinib for Patients with Rare and Hard-to-Treat Cancers

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Dabrafenib
  • Sponsor:Oslo University Hospital HF

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.